| Literature DB >> 26683233 |
Stephen A Cooper1, Paul J Desjardins, Dennis C Turk, Robert H Dworkin, Nathaniel P Katz, Henrik Kehlet, Jane C Ballantyne, Laurie B Burke, Eugene Carragee, Penney Cowan, Scott Croll, Raymond A Dionne, John T Farrar, Ian Gilron, Debra B Gordon, Smriti Iyengar, Gary W Jay, Eija A Kalso, Robert D Kerns, Michael P McDermott, Srinivasa N Raja, Bob A Rappaport, Christine Rauschkolb, Mike A Royal, Märta Segerdahl, Joseph W Stauffer, Knox H Todd, Geertrui F Vanhove, Mark S Wallace, Christine West, Richard E White, Christopher Wu.
Abstract
This article summarizes the results of a meeting convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) on key considerations and best practices governing the design of acute pain clinical trials. We discuss the role of early phase clinical trials, including pharmacokinetic-pharmacodynamic (PK-PD) trials, and the value of including both placebo and active standards of comparison in acute pain trials. This article focuses on single-dose and short-duration trials with emphasis on the perioperative and study design factors that influence assay sensitivity. Recommendations are presented on assessment measures, study designs, and operational factors. Although most of the methodological advances have come from studies of postoperative pain after dental impaction, bunionectomy, and other surgeries, the design considerations discussed are applicable to many other acute pain studies conducted in different settings.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26683233 DOI： 10.1097/j.pain.0000000000000375
Source DB: PubMed Journal: Pain ISSN： 0304-3959 Impact factor: 6.961